Chong Kun Dang to launch anti-clotting agent

Published: 2008-06-04 06:55:00

Updated: 2008-06-04 06:55:00

Chong Kun Dang Pharmaceutical is considering launching its chemical modified Prigrel tablet (clopidogrel reginate) in the domestic thrombolytic market dominated by Sanofi-Aventis’s Plavix (clopidogrel bisulfate).

Plavix’s last year sales amounted to 110 billion won, ranking a top position in t...

Fees

- Email service daily and homepage access.

$300 per month. ($3,240 per year)
5 Email holders per each company.
Anual contract base.

Latest News

Which are outstanding tetravalent vaccines even for the young?

Disease treated the most with clinical trial drugs is respiratory disorder like lung cancer

Who will be the next Pharmaceutical Safety Bureau Director?

Celltrion completes clinical trials for Remsima SC for European approval

Sales listed pharmas made in the first half of the year

TOP

BACK